To determine whether FAK and/or RAF/MEK inhibition reduces melanoma cell proliferation, YUMM3.2;Pten−/−;Akt1E17K cells were treated with increasing doses of either VS-4718, which is an ATP-competitive FAKi and surrogate for defactinib, or avutometinib for 72 h. Here, MAP2K7 is linked to melanoma.